Oversight of the Office of National Drug Control Policy (ONDCP) and its 2022 National Drug Control Strategy

Washington, DC – At 2 p.m. on Wednesday, June 15, the Senate Caucus on International Narcotics Control held a hearing entitled, “Oversight of the Office of National Drug Control Policy (ONDCP) and its 2022 National Drug Control Strategy,” in Room 608 of the Dirksen Senate Office Building.  The hearing examined the National Drug Control Strategy and its compliance with ONDCP’s statutory authorization.

Panel 1

Rahul Gupta, MD, MPH, MBA, FACP, Director, ONDCP (testimony)

Panel 2

Triana McNeil, Director, Strategic Issues, Government Accountability Office (testimony)

Established in 1985, the Senate Caucus on International Narcotics Control, consists of seven members, with four belong to the majority party.  The Caucus, which is authorized in law and has the status of a standing committee, has held hearings on strengthening U.S. counter-narcotics efforts around the world, narcotics-related corruption, as well as addressing the drug overdose epidemic in America.  In the past decade, the Caucus has drafted reports on the drug trade in Afghanistan, the Caribbean, Mexico, and West Africa, and the connection between U.S. money laundering and organized crime.

NNOAC Statement for the Record available here.

RAND Statement for the Record available here.

NHDA Statement for the Record available here.